Clinical Development of Novel Drug-Radiotherapy Combinations.
Document Type
Article
Publication Date
11-29-2018
Publication Title
Clinical cancer research : an official journal of the American Association for Cancer Research
Abstract
Radiotherapy is a fundamental component of treatment for the majority of patients with cancer. In recent decades, technological advances have enabled patients to receive more targeted doses of radiation to the tumor, with sparing of adjacent normal tissues. There had been hope that the era of precision medicine would enhance the combination of radiotherapy with targeted anticancer drugs; however, this ambition remains to be realized. In view of this lack of progress, the FDA-AACR-ASTRO Clinical Development of Drug-Radiotherapy Combinations Workshop was held in February 2018 to bring together stakeholders and opinion leaders from academia, clinical radiation oncology, industry, patient advocacy groups, and the FDA to discuss challenges to introducing new drug-radiotherapy combinations to the clinic. This
Clinical Institute
Cancer
Department
Oncology
Department
Earle A. Chiles Research Institute
Recommended Citation
Ahmad, Saif S; Crittenden, Marka R; Tran, Phuoc T; Kluetz, Paul G; Blumenthal, Gideon M; Bulbeck, Helen; Baird, Richard D; Williams, Kaye J; Illidge, Tim; Hahn, Stephen M; Lawrence, Theodore S; Spears, Patricia A; Walker, Amanda J; and Sharma, Ricky A, "Clinical Development of Novel Drug-Radiotherapy Combinations." (2018). Articles, Abstracts, and Reports. 979.
https://digitalcommons.providence.org/publications/979
